Nedaplatin (JiebaishuÂ®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is a second-generation platinum compound that is more active against squamous cell carcinoma of the lung with a response rate of 60%, issued by the finished Phase II trial in Japan.
Squamous Cell Carcinoma
DRUG: Nedaplatin|DRUG: Cisplatin|DRUG: Docetaxel
progress free survival, after being enrolled, the subjects will be subject to 4 cycles chemotherapy (each cycle: 21 days). if complete response/partial response/stable desease is confirmed, the subjects will be followed up till to the sixth months., 9 months
Objective Response Rate, the effectiveness will be evaluated after 2 cycles of chemotherapy is finished. 4 cycles of chemotherapy is needed for each subject., 3 months
Adverse Events, Adverse Events will be recorded and monitored till to normal or basal level achieved., 10 months
The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is a second-generation platinum compound that is more active against squamous cell carcinoma of the lung with a response rate of 60%, issued by the finished Phase II trial in Japan.